Suzhou HKeyBio

HKey Bio is a clinical-stage biotechnology company headquartered in Suzhou, China, dedicated to the discovery and development of transformative gene therapies. The company leverages its proprietary adeno-associated virus (AAV) vector technology to target rare genetic disorders and chronic metabolic diseases. Its lead programs, GS001 and GS002, are currently in clinical development for the treatment of Hemophilia A and Hemophilia B, respectively. HKey Bio operates a comprehensive platform that spans from early-stage research to large-scale GMP manufacturing. The firm is backed by prominent investors including Sequoia China and Hillhouse Capital, aiming to deliver curative solutions for patients with high unmet medical needs.